Novel sst4-Selective Somatostatin (SRIF) Agonists. 2. Analogues with β-Methyl-3-(2-naphthyl)alanine Substitutions at Position 8

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5587-5596

  Erchegyi, Judit ^a   Penke, Botond ^c   Simon, Lajos ^c   Michaelson, Scott ^a   Wenger, Sandra ^b   Waser, Beatrice ^b   Cescato, Renzo ^b   Schaer, Jean Claude ^b   Reubi, Jean Claude ^b   Rivier, Jean ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE DERIVATIVE; BETA METHYL 3 (NAPHTHYL)ALANINE; CYCLIC AMP; CYSTEINE; LIGAND; OCTAPEPTIDE; PHENYLALANINE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN AGONIST; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; DIASTEREOISOMER; IC 50; IODINATION; RECEPTOR AFFINITY; RECEPTOR BINDING; STEREOISOMERISM;

ALANINE; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CYCLIC AMP; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LIGANDS; MEMBRANE PROTEINS; NAPHTHALENES; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10744223244     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0302445     Document Type: Article

References (75)

1. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179, 77-79.
2. Guillemin, R.; Gerich, J. E. Somatostatin: physiological and clinical significance. Annu. Rev. Med. 1976, 27, 379-388.
3. Reichlin, S. Somatostatin. N. Engl. J. Med. 1983, 309, 1495-1501.
4. Reichlin, S. Somatostatin (second of two parts). N. Engl. J. Med. 1983, 309, 1556-1563.
5. Epelbaum, J. Somatostatin in the central nervous system: physiology and pathological modification. Prog. Neurobiol. 1986, 27, 63-100.
6. Sassolas, G. The role of Sandostatin in acromegaly. Metabolism: Clin., Exp. 1992, 41, 39-43.
7. Wynick, D.; Bloom, S. R. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J. Clin. Endocrinol. Metab. 1991, 73, 1-3.
8. Janecka, A.; Zubrzycka, M.; Janecki, T. Review: Somatostatin analogs. J. Pept. Res. 2001, 58, 91-107.
9. Schally, A. V.; Comaru-Schally, A. M.; Nagy, A.; Kovacs, M.; Szepeshazi, K.; Plonowski, A.; Varga, J. L.; Halmos, G. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 2001, 22, 248-291.
10. Hannon, J. P.; Nunn, C.; Stolz, B.; Bruns, C.; Weckbecker, G.; Lewis, I. ; Troxler, T.; Hurth, K.; Hoyer, D. Drug design at peptide receptors: somatostatin receptor ligands. J. Mol. Neurosci. 2002, 18, 15-27.
11. de Herder, W. W.; Lamberts, S. W. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. 2002, 14, 53-57.
12. Reisine, T.; Bell, G. I. Molecular biology of somatostatin receptors. Endocrine Rev. 1995, 16, 427-442.
13. Patel, Y. C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20, 157-198.
14. Afargan, M.; Janson, E. T.; Gelerman, G.; Rosenfeld, R.; Ziv, O.; Karpov, O.; Wolf, A.; Bracha, M.; Shohat, D.; Liapakis, G.; Gilon, C.; Hoffman, A.; Stephensky, D.; Oberg, K. Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin. Endocrinology 2001, 142, 477-486.
15. 4 selectivity: Synthesis and structure-activity relationships of thioureas. J. Med. Chem. 1998, 41, 4693-4705.
16. Schloos, J.; Raulf, F.; Hoyer, D.; Bruns, C. Identification and pharmacological characterization of somatostatin receptors in rat lung. Br. J. Pharmacol. 1997, 121, 963-971.
17. 4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy. J. Clin. Endocrinol. Metab. 1997, 82, 3771-3776.
18. 4 receptor protein in selected human brain areas: an immunohistochemical study. Mol. Brain Res. 2000, 82, 114-125.
19. 4 somatostatin receptor in rat brain. J. Neurosci. 2000, 20, 3785-3797.
20. 4 receptor in rat brain. Neuroscience 2000, 98, 523-533.
21. Schulz, S.; Schmitt, J.; Quednow, C.; Roessner, A.; Weise, W. Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gynecol. Oncol. 2002, 84, 235-240.
22. Bell, G. I.; Yasuda, K.; Kong, H.; Law, S. F.; Raynor, K.; Reisine, T. Molecular biology of somatostatin receptors. Somatostatin and its Receptors; Ciba Foundation Symposium 190, London, England, July 12-14, 1994; Wiley: Chichester, 1995; pp 65-79.
23. Lamberts, S. W.; van der Lely, A. J.; de Herder, W. W.; Hofland, L. J. Octreotide. N. Engl. J. Med. 1996, 334, 246-254.
24. Ankersen, M.; Crider, M.; Liu, S.; Ho, B.; Andersen, H. S.; Stidsen, C. Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity. J. Am. Chem. Soc. 1998, 120, 1368-1373.
25. Rohrer, S. P.; Birzin, E. T.; Mosley, R. T.; Berk, S. C.; Hutchins, S. M.; Shen, D.-M.; Xiong, Y.; Hayes, E. C.; Parmar, R. M.; Foor, F.; Mitra, S. W. ; Degrado, S. J.; Shu, M.; Klopp, J. M.; Cai, S.-J.; Blake, A.; Chan, W. W. S.; Pasternak, A.; Yang, L.; Patchett, A. A.; Smith, R. G.; Chapman, K. T.; Schaeffer, J. M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282, 737-740.
26. Souers, A. J.; Rosenquist, A.; Jarvie, E. M.; Ladlow, M.; Feniuk, W.; Ellman, J. A. Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation. Bioorg. Med. Chem. Lett. 2000, 10, 2731-2733.
27. Gademann, K.; Kimmerlin, T.; Hoyer, D.; Seebach, D. Peptide folding induces high and selective affinity of a linear and small β-peptide to the human somatostatin receptor 4. J. Med. Chem. 2001, 44, 2460-2468.
28. Gazal, S.; Gelerman, G.; Ziv, O.; Karpov, O.; Litman, P.; Bracha, M.; Afargan, M.; Gilon, C. Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J. Med. Chem. 2002, 45, 1665-1671.
29. Jiang, S.; Gazal, S.; Gelerman, G.; Ziv, O.; Karpov, O.; Litman, P.; Bracha, M.; Afargan, M.; Gilon, C.; Goodman, M. A bioactive somatostatin analog without a type II′ β-turn: Synthesis and conformational analysis in solution. J. Pept. Sci. 2001, 7, 521-528.
30. Hruby, V. J. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 1982, 31, 189-199.
31. Boteju, L. W.; Wegner, K.; Qian, X.; Hruby, V. J. Asymmetric synthesis of unusual amino acids: Synthesis of optically pure isomers of N-indole-(2-mesitylenesulfonyl)-β-methyltryptophan. Tetrahedron 1994, 50, 2391-2404.
32. Hruby, V. J.; Li, G.; Haskell-Luevano, C.; Shenderovich, M. Design of peptides, proteins, and peptidomimetics in Chi space. Biopolymers 1997, 43, 219-266.
33. Kataoka, Y.; Seto, Y.; Yamamoto, M.; Yamada, T.; Kuwata, S.; Watanabe, H. Studies of unusual amino acids and their peptides. VI. The syntheses and the optical resolutions of β-methylphenylalanine and its dipeptide present in bottromycin. Bull. Chem. Soc. Jpn. 1976, 49, 1081-1084.
34. Dharanipragada, R.; Nicolas, E.; Toth, G.; Hruby, V. J. Asymmetric synthesis of unusual amino acids: Synthesis of optically pure isomers of β-methylphenylalanine. Tetrahedron Lett. 1989, 30, 6841-6844.
35. Dharanipragada, R.; VanHulle, K.; Bannister, A.; Bear, S.; Kennedy, L.; Hruby, V. J. Asymmetric synthesis of unusual amino acids: An efficient synthesis of optically pure isomers of β-methylphenylalanine. Tetrahedron 1992, 48, 4733-4748.
36. Pasto, M.; Moyano, A.; Pericas, M. A.; Riera, A. A catalytic asymmetric synthesis of N-Boc-β-Methylphenylalanines. J. Org. Chem. 1997, 62, 8425-8431.
37. Nicolas, E.; Dharanipragada, R.; Toth, G.; Hruby, V. J. Asymmetric synthesis of unusual amino acids: Synthesis of optically pure isomers of β-methyltyrosine. Tetrahedron Lett. 1989, 30, 6845-6848.
38. Boteju, L. W.; Wegner, K.; Hruby, V. J. Asymmetric synthesis of unusual amino acids: Synthesis of the optically pure isomers of indole-protected β-methyltryptophan suitable for peptide synthesis. Tetrahedron Lett. 1992, 33, 7491-7494.
39. Han, G.; Lewis, A.; Hruby, V. J. Synthesis of (2S,3S)-β -methyltryptophan. Tetrahedron Lett. 2001, 42, 4601-4603.
40. Nemes, C.; Jeannin, L.; Sapi, J.; Laronze, M.; Seghir, H.; Augé, F.; Laronze, J.-Y. A convenient synthesis of conformationally constrained β-substituted tryptophans. Tetrahedron 2000, 56, 5479-5492.
41. Hoermer, R. S.; Askin, D.; Volante, R. P.; Reider, P. J. A highly eneantioselective asymmetric hydrogenation route to β -(2R,3S)-methyltryptophan. Tetrahedron Lett. 1998, 39, 3455-3458.
42. Li, G.; Boteju, L. W.; Patel, D.; Hruby, V. J. A new method for the synthesis of the optically pure precursors to β-methyl derivatives of tryptophan, histidine, tyrosine and phenylalanine. Synth. Methods 1994, 181-183.
43. Lebl, M.; Toth, G.; Slanniova, J.; Hruby, V. J. Conformationally biased analogs of oxytocin. Int. J. Pept. Protein Res. 1992, 40, 148-151.
44. Yuan, W.; Hruby, V. J. Asymmetric synthesis of unusual amino acid: Synthesis of four isomers of β-methyl-3-(2′-naphthyl)-alanine. Tetrahedron Lett. 1997, 38, 3853-3856.
45. Huang, Z.; He, Y.; Raynor, K.; Tallent, M.; Reisine, T.; Goodman, M. Side chain chiral methylated somatostatin analog synthesis and conformational analysis. J. Am. Chem. Soc. 1992, 114, 9390-9401.
46. Tourwé, D.; Verschueren, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Toth, G.; Jaspers, H.; Verheyden, P.; Van Binst, G. Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology. Biopolymers 1996, 38, 1-12.
47. Tourwé, D.; Mannekens, E.; Nguyen Thi Diem, T.; Verheyden, P.; Jaspers, H.; Tóth, G.; Péter, A.; Kertész, I.; Török, G.; Chung, N. N.; Schiller, P. W. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. J. Med. Chem. 1998, 41, 5167-5176.
48. Sagan, S.; Josien, H.; Karoyan, P.; Brunissen, A.; Chassaing, G.; Lavielle, S. Tachykinin NK-1 receptor probed with constrained analogues of substance P. Bioorg. Med. Chem. 1996, 4, 2167-2178.
49. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
50. 3]deltorphin I. J. Pept. Res. 2001, 57, 257-276.
51. Liao, S.; Lin, J.; Shenderovich, M. D.; Han, Y.; Hasohata, K.; Davis, P. ; Qiu, W.; Porrea, F.; Yamamura, H. I.; Hruby, V. J. The stereochemical requirements of the novel δ-opioid selective dipeptide antagonist TMT-TIC. Bioorg. Med. Chem. Lett. 1997, 7, 3049-3052.
52. Liao, S.; Shenderovich, M. D.; Zhang, Z.; Maletinska, L.; Slaninova, J.; Hruby, V. J. Substitution of the side-chain-constrained amino acids β-methyl-2′,6′-dimethyl-4′-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J. Am. Chem. Soc. 1998, 120, 7393-7394.
53. Haskell-Luevano, C.; Boteju, L. W.; Miwa, H.; Dickinson, C.; Gantz, I.; Yamada, T.; Hadley, M. E.; Hruby, V. J. Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. J. Med. Chem. 1995, 38, 4720-4729.
54. 4-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. J. Med. Chem. 2003, 46, 5579-5586 (in this issue).
55. Rivier, J. E.; Jiang, G.-C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Hoeger, C. Betidamino acids: Versatile and constrained scaffolds for drug discovery. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2031-2036.
56. Reubi, J. C.; Schaer, J.-C.; Wenger, S.; Hoeger, C.; Erchegyi, J.; Waser, B.; Rivier, J. SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13973-13978.
57. Patel, Y. C.; Panetta, R.; Escher, E.; Greenwood, M.; Srikant, C. B. Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. J. Biol. Chem. 1994, 269, 1506-1509.
58. Vale, W.; Rivier, C.; Rivier, J.; Brown, M. Diverse roles of hypothalamic regulatory peptides. Medicinal Chemistry V; Elsevier Scientific: Amsterdam, 1977; pp 22-62.
59. Vale, W.; Rivier, C.; Brown, M.; Rivier, J. Pharmacology of TRF, LRF and somatostatin. Hypothalamic Peptide Hormones and Pituitary Regulation: Advances in Experimental Medicine and Biology; Plenum Press: New York, 1977; pp 123-156.
60. Vale, W.; Rivier, J.; Ling, N.; Brown, M. Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978, 27, 1391-1401.
61. Shoji, J.-I.; Tori, K.; Otsuka, H. Configuration of N,β -dimethylleucine, a constituent amino acid of triostin C. J. Org. Chem. 1964, 30, 2772-2776.
62. Miller, C.; Rivier, J. Peptide chemistry: Development of high-performance liquid chromatography and capillary zone electrophoresis. Biopolymers 1996, 40, 265-317.
63. 1). J. Med. Chem. 2001, 44, 2238-2246.
64. Reubi, J. C.; Schaer, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Mäcke, H. R. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
65. 1-receptor subtype expressed by human tumors. Eur. J. Pharmacol. 1998, 345, 103-110.
66. Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. Highly potent cyclic disulfide antagonists of somatostatin. J. Med. Chem. 1999, 42, 1863-1871.
67. Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Morgan, B.; Coy, D. H. Potent antagonists of somatostatin: Synthesis and biology. J. Med. Chem. 1998, 41, 1146-1154.
68. Bass, R. T.; Buckwalter, B. L.; Patel, B. P.; Pausch, M. H. P. L. A.; Strnad, J.; Hadcock, J. R. Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 1996, 50, 709-715.
69. 4-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. J. Med. Chem. 2003, 46, 5597-5605 (in this issue).
70. 4-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR. 2003, 46, 5606-5618 (in this issue).
71. Horiki, K.; Igano, K.; Inouye, K. Amino acids and peptides. Part 6. Synthesis of the Merrifield resin esters of N-protected amino acids with the aid of hydrogen bonding. Chem. Lett. 1978, 2, 165-168.
72. Rivier, J.; Porter, J.; Hoeger, C.; Theobald, P.; Craig, A. G.; Dykert, J.; Corrigan, A.; Perrin, M.; Hook, W. A.; Siraganian, R. P.; Vale, W.; Rivier, C. Gonadotropin releasing hormone antagonists with Nω-triazolyl-ornithine, -lysine or -para-aminophenylalanine residues at positions 5 and 6. J. Med. Chem. 1992, 35, 4270-4278.
73. Lutz, O.; Jirgensons, B. Über eine neue Methode der Zuteilung optisch-aktiver α-Amino säuren zur Rechts- oder Lnks- reihe (L Mitteil.). Chem. Ber. 1930, 63, 448-460.
74. Stewart, J. M.; Young, J. D. Solid-Phase Peptide Synthesis. Solid-Phase Peptide Synthesis, 2nd ed.; Pierce Chemical Co.: Rockford, IL, 1984; p 176.
75. Reubi, J. C.; Eisenwiener, K. P.; Rink, H.; Waser, B.; Macke, H. R. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. 2002, 456, 45-49.